Analyst Price Targets — SMMT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 4, 2026 10:15 am | — | H.C. Wainwright | $23.00 | $16.12 | TheFly | Summit Therapeutics price target lowered to $23 from $30 at H.C. Wainwright |
| May 1, 2026 11:06 am | — | Piper Sandler | $16.00 | $21.46 | TheFly | Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler |
| February 24, 2026 11:57 am | — | H.C. Wainwright | $30.00 | $16.09 | TheFly | Summit Therapeutics price target lowered to $30 from $40 at H.C. Wainwright |
| January 14, 2026 11:54 am | — | Piper Sandler | $40.00 | $16.89 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT) |
| December 17, 2025 7:58 am | Etzer Darout | Summit Redstone Partners | $18.00 | $17.23 | StreetInsider | Barclays Upgrades Summit Therapeutics plc (SMMT) to Equalweight |
| October 21, 2025 10:42 am | — | H.C. Wainwright | $40.00 | $20.04 | StreetInsider | Summit Therapeutics plc (SMMT) PT Lowered to $40 at H.C. Wainwright |
| October 21, 2025 9:35 am | — | Barclays | $16.00 | $20.04 | TheFly | Summit Therapeutics price target raised to $16 from $13 at Barclays |
| September 16, 2025 9:04 pm | — | Summit Redstone Partners | $13.00 | $18.12 | TheFly | Summit Therapeutics initiated with an Underweight at Barclays |
| August 19, 2025 10:31 am | Kelsey Goodwin | Summit Redstone Partners | $21.00 | $25.71 | TheFly | Piper starts Summit Therapeutics with Neutral on high expectations |
| April 28, 2025 10:11 am | — | H.C. Wainwright | $44.00 | $24.11 | TheFly | Summit Therapeutics selloff Friday on data overdone, says H.C. Wainwright |
Latest News for SMMT
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) will host a conference call to announce its second quarter 2026 financial results and provide an update on operational progress on Thursday, July 23, 2026. The call is scheduled to take place at 4:30 p.m. EDT. The live and archived webcast can be accessed through the Investor Information section of the company's website, www.smmttx.com. About…
SMMT divests investigational antibiotic ridinilazole to Biossil for upfront cash, milestone payments and royalties as it sharpens its focus on oncology.
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigat
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned by Summit. Biossil is an artificial intelligence (AI)-native biopharma company focused on advancing late-stage programs in life-threatening indications with urgent unmet medical…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SMMT.
U.S. House Trading
No House trades found for SMMT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.